AZNCF News and Press, AstraZeneca Plc From 11/10/22

AstraZeneca PLC (AZN) Q3 2022 Earnings Conference Call November 10, 2022 06:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO David Fredrickson - Exec...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q3 earnings call. For further details see: AstraZeneca PLC 2022 Q3 - Results - Earnings Call Presentation

Summary Fisher’s 13F portfolio value decreased from ~$141B to ~$133B in Q3 2022. They added Charles Schwab and increased Nvidia, Morgan Stanley, and Goldman Sachs while decreasing Salesforce, Visa, Alibaba Group Holdings, Novartis, Verizon, and Tencent Holdings. The top...

Summary AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintainin...

Summary Global growth stocks held up better than value, snapping a two-quarter losing streak, as global recession fears weighed more heavily on companies tied to the broader economy. The Strategy outperformed for the second quarter in a row, thanks in large part to positioning adj...

Summary The combination of extremely depressed stocks and improving fundamentals is a powerfully bullish combination for long-term value investors. Despite being at all-time historical lows, the market is pricing financials and energy stocks as if they have the greatest earnings r...

Summary AstraZeneca plans to grow beyond 2025 by building its innovation pipeline. Investors in the target benefit when a big pharma company acquires an emerging company. Starpharma is an example of a company that might be of interest to a big pharma acquirer. Rarely, emer...

Summary Investors are flocking to USD, and most foreign currencies are now weak. On the surface, investment implications seem slight, but it is quite the contrary. This article will highlight the current market implications and ways that a strong USD influences foreign assets....

Summary GSK's price might have underwhelmed recently, but it's picking up now, calling for a closer look at it after a demerger with its consumer healthcare division last quarter. It's largely well placed to face macroeconomic pressures of slow growth, high inflation, and rising i...

Summary Europe's economic metrics held up decently in the first half of this year, giving rise to some optimism in regards to the economic fallout from its economic divorce with Russia. Deutsche Bank recently released an estimate for EU 2023 GDP growth of -2.2%. I believe that it ...